In order to support the long-term supply of its biologic agent, HUMIRA (adalimumab), as well as future biologics, Abbott opened a new biologics manufacturing facility (ABL) in Puerto on April 10.
"This new facility is a key milestone for Abbott as we move to focus
our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott. "The advanced, high-quality infrastructure of ABL can meet the exceptionally challenging and stringent processes of biologic
manufacturing."
The new plant is Abbott's single-largest capital investment to date, costing approximately $450 million. With this investment, Abbott says it can achieve large-scale production volumes in biologic manufacturing. In addition to producing HUMIRA, the 330,000-sq.-ft. facility is designed for large-scale production of future products in Abbott's pipeline that will require advanced manufacturing technologies.
"Puerto Rico has been a global leader in manufacturing pharmaceutical products for more than 40 years. Our unique combination of incentives, skilled workforce, strong infrastructure and excellent business climate enable us to partner with global industry leaders like Abbott," said Hon. Anibal Acevedo-Vila, Governor of the Commonwealth of Puerto Rico
Since establishing operations on the island in 1968, Abbott has invested more than $1 billion in its Barceloneta, Puerto Rico, site. The company also has manufacturing operations in Puerto Rico at Jayuya and Dorado, as well as commercial operations in San Juan and a distribution center in Guaynabo.
